Patent Ductus Arteriosus

Subscribe to Selected New Research on Patent Ductus Arteriosus

1300 relevant articles (58 outcomes, 124 trials/studies) found for this Disease

Description: A congenital heart defect characterized by the persistent opening of fetal DUCTUS ARTERIOSUS that connects the PULMONARY ARTERY to the descending aorta (AORTA, DESCENDING) allowing unoxygenated blood to bypass the lung and flow to the PLACENTA. Normally, the ductus is closed shortly after birth.

Also Known As:

Ductus Arteriosus, Patent; Arteriosus, Patent Ductus

Relationship Network

Disease Context: Research Results

Cardiovascular Diseases: 18525

Heart Diseases: 12357

Congenital Heart Defects: 687

Patent Ductus Arteriosus: 1300

Cardiovascular Abnormalities: 167

Congenital Heart Defects: 687

Patent Ductus Arteriosus: 1300

Congenital, Hereditary, and Neonatal Diseases and Abnormalities: 422

Congenital Abnormalities: 9332

Cardiovascular Abnormalities: 167

Congenital Heart Defects: 687

Patent Ductus Arteriosus: 1300

Related Diseases

1.	Hemorrhage
2.	Pneumothorax
3.	Pulmonary Hypertension (Ayerza Syndrome)
4.	Birth Weight (Birth Weights)
5.	Hyaline Membrane Disease

Experts

1.	Ohlsson, A: 7 articles (01/2008 - 01/2003)
2.	Shah, S: 5 articles (01/2008 - 01/2003)
3.	Vedovato, Stefania: 3 articles (05/2008 - 11/2005)
4.	Faggian, Diego: 3 articles (05/2008 - 11/2005)
5.	Van Overmeire, Bart: 3 articles (05/2008 - 04/2003)
6.	Lee, Jiun: 3 articles (05/2008 - 08/2003)
7.	Clyman, Ronald I: 3 articles (05/2008 - 09/2003)
8.	Zanardo, Vincenzo: 3 articles (05/2008 - 11/2005)
9.	Walia, R: 3 articles (01/2008 - 01/2003)
10.	Lago, Paola: 3 articles (11/2005 - 04/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Patent Ductus Arteriosus:

1.	Indomethacin (Indometacin)FDA LinkGeneric 06/01/1988 - "Indomethacin has proven effective in closing the patent ductus arteriosus (PDA) in most low birth weight (LBW) neonates with this disorder" 12/01/1978 - "A series of 33 consecutive preterm newborns who were treated with indomethacin, a drug which acts to close the patent ductus arteriosus, were studied retrospectively to examine the efficacy of chest radiography and echocardiography in diagnosing the presence of a significant patent ductus arteriosus" 04/01/2004 - "Is oral indomethacin effective in treatment of preterm infants with patent ductus arteriosus?" 11/01/1998 - "Postnatally, therapeutic indomethacin administration is usually effective in mediating patent ductus arteriosus (PDA) constriction in premature infants" 09/01/1993 - "Indomethacin has been demonstrated to be effective for closure of hemodynamically symptomatic patent ductus arteriosus (PDA) in premature infants" Order ALL the reference details at left...
2.	Ibuprofen (Motrin)FDA LinkGeneric 05/01/2000 - "This study was aimed at evaluating the efficacy of ibuprofen in the prophylaxis of patent ductus arteriosus (PDA) in very preterm neonates and at detecting eventual side-effects" 01/01/1998 - "Is ibuprofen a useful treatment for patent ductus arteriosus?" 05/01/2008 - "An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study." 05/01/2007 - "The purpose of this study was to evaluate the feasibility of the use oral ibuprofen suspension (OIS) in the treatment of patent ductus arteriosus (PDA) in premature infants" 04/01/2005 - "Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method." Order ALL the reference details at left...
3.	Furosemide (Lasix)FDA LinkGeneric 01/01/2008 - "Furosemide-induced transient improvement in pulmonary function did not outweigh an increased risk for patent ductus arteriosus and for hemodynamic instability" 01/01/2001 - "Furosemide-induced transient improvement in pulmonary function did not outweigh an increased risk for patent ductus arteriosus and for hemodynamic instability" 01/01/2000 - "Furosemide-induced transient improvement in pulmonary function did not outweigh an increased risk for patent ductus arteriosus and for hemodynamic instability" 01/01/2001 - "In addition, elective administration of furosemide should be weighed against the risk of developing a symptomatic patent ductus arteriosus." 01/01/2000 - "In addition, elective administration of furosemide should be weighed against the risk of developing a symptomatic patent ductus arteriosus." Order ALL the reference details at left...
4.	beta-apocarotenoid-14',13'-dioxygenase (ADO)IBA 09/01/2005 - "The Amplatzer duct occluder (ADO) provides a safe and effective therapy for patients with moderate- to large-sized patent ductus arteriosus (PDA), but there have been few reports of transcatheter closure of very large PDAs in young children and infants" 01/01/2001 - "OBJECTIVES: The aim of the study was to assess the safety and efficacy of the Amplatzer ductal occluder (ADO) in transcatheter occlusion of patent ductus arteriosus (PDA)" 07/15/2004 - "This study compared the efficacy and costs of the most used approaches for percutaneous closure of large patent ductus arteriosus, that is, multiple coils and the Amplatzer duct occluder (ADO) device" 02/01/2003 - "In the present study, we report the initial clinical experience with the new angled Amplatzer duct occluder (ADO) for the percutaneous closure of patent ductus arteriosus (PDA)" 03/15/2000 - "OBJECTIVE: The aim of this study was to report further experience with transcatheter closure of the patent ductus arteriosus (PDA) using the Amplatzer duct occluder (ADO)" Order ALL the reference details at left...
5.	SteroidsIBA 01/01/2003 - "There was a statistically significant increase in the rate of patent ductus arteriosus (RR 1.64, 95% CI 1.23, 2.17; RD 0.21, 95% CI 0.10, 0.33; 1 trial and n = 278) in the group receiving inhaled steroids" 07/01/2007 - "When intermediate risk factors for BPD were also added to the model, the effect of steroids disappeared; ventilation (OR = 3.03), increased illness severity (OR = 1.11), and patent ductus arteriosus (OR = 1.90) were significant risk factors" 07/01/1998 - "Birthweight, gestational age, race, day of first extubation, antenatal or postnatal steroids, patent ductus arteriosus status and maximal mean airway pressure used were of no value in predicting success or failure at 72 hours, 1, or 2 weeks" 07/01/2007 - "In univariable analysis, steroids were not significantly protective against BPD; some intermediate factors (mechanical ventilation, greater severity of illness as measured by Clinical Risk Index for Babies score, patent ductus arteriosus) were significantly positively associated with (i.e" 03/01/2008 - "Prenatal steroids, gestational age, place of birth, type of hospital, CRIB score, symptomatic patent ductus arteriosus and late-onset bacterial sepsis were related with the shift in weight z score at 28 days (multiple linear regression), but explained very little (14 %) of his change" Order ALL the reference details at left...
6.	nitinolIBA 07/01/1995 - "PURPOSE: To assess the safety and efficacy of the nitinol snare to aid in the delivery of a Gianturco coil in percutaneous occlusion of a patent ductus arteriosus (PDA)" 09/01/2002 - "First closure of a large patent ductus arteriosus in an infant with an angulated nitinol plug." 05/01/1998 - "Nonsurgical transcatheter coil occlusion of patent ductus arteriosus in two dogs using a preformed nitinol snare delivery technique." 07/01/1995 - "Percutaneous transcatheter coil occlusion of the patent ductus arteriosus aided by the nitinol snare: further observations." 10/15/1994 - "Use of preformed nitinol snare to improve transcatheter coil delivery in occlusion of patent ductus arteriosus." Order ALL the reference details at left...
7.	OxygenIBA 01/01/2008 - "Subsequent and adequate treatment of a patent ductus arteriosus may prevent diminished cerebral perfusion and subsequent decreased oxygen delivery, which reduces the change of damage to the vulnerable immature brain." 01/01/2008 - "RESULTS: Mean arterial blood pressure and regional cerebral oxygen saturation were significantly lower and fractional tissue oxygen extraction significantly higher compared with the control infants during patent ductus arteriosus (mean arterial blood pressure: 33 +/- 5 vs 38 +/- 6 mmHg; regional cerebral oxygen saturation: 62% +/- 9% vs 72% +/- 10%; fractional tissue oxygen extraction: 0.34 +/- 0.1 vs 0.25 +/- 0.1, respectively)" 01/01/2008 - "Although patent ductus arteriosus induces alterations in organ perfusion, scarce information is available of the impact of patent ductus arteriosus and its subsequent treatment on the oxygen supply and oxygen extraction of the brain" 04/01/2007 - "In the 25-27 weeks subgroup, delivery room intubation, surfactant treatment and patent ductus arteriosus (PDA) were less frequent in ACS infants; they had also shorter ventilation and oxygen duration" 09/14/2004 - "Oxygen-sensitive Kv channel gene transfer confers oxygen responsiveness to preterm rabbit and remodeled human ductus arteriosus: implications for infants with patent ductus arteriosus." Order ALL the reference details at left...
8.	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 09/15/1979 - "Premature onset of labor, neonatal patent ductus arteriosus, and prostaglandin synthetase antagonists--a rat model of a human problem." 01/01/2006 - "The aims of our study were to determine the mortality and morbidity following patent ductus arteriosus ligation in premature infants, and whether prostaglandin synthetase inhibitor (PSI) use prior to ligation affects outcome" 01/01/1984 - "These factors (immaturity, hyperoxia, hypoxia, blood transfusions, intraventricular hemorrhage, apnea, infection, hypercarbia, hypocarbia, patent ductus arteriosus, prostaglandin synthetase inhibitors, vitamin E deficiency, lactic acidosis, prenatal complications, genetic factors) may all be present in an infant" 01/01/2004 - "BACKGROUND: Ibuprofen is a cyclooxygenase inhibitor that is effective in treating patent ductus arteriosus in preterm infants" 01/01/1988 - "Indomethacin, a prostaglandin synthetase inhibitor used for the pharmacological closure of a patent ductus arteriosus, also increases renal vascular resistance, and decreases urine output" Order ALL the reference details at left...
9.	PlatinumIBA 02/01/2003 - "BACKGROUND: The purpose of the present study was to develop a method to occlude a patent ductus arteriosus (PDA) using a tornado platinum coil, which is compatible with magnetic fields" 02/01/2003 - "Transcatheter occlusion of patent ductus arteriosus using tornado platinum coils." 07/01/2003 - "A 19-year-old girl with coarctation of the aorta and patent ductus arteriosus underwent simultaneous treatment of native coarctation and closure of ductus arteriosus using a covered Cheatham-Platinum stent" 01/01/1999 - "RATIONALE AND OBJECTIVE: The authors assess the clinical efficacy of transvenous closure of patent ductus arteriosus (PDA) with a new plug consisting of Ivalon foam and a platinum/iridium frame with four aortic and two pulmonary nitinol struts" Order ALL the reference details at left...
10.	Exosurf (Exosurf Neonatal)FDA Link 11/01/1996 - "An unreliable reduction of pulmonary vascular resistance and increase of volumic pulmonary blood flow were observed as soon as during the first minutes after administration of exosurf; this was not paralleled by a pathological increase of the left-right shunting of the blood through patent ductus arteriosus" 01/01/2000 - "In individual trials, the use of Exosurf Neonatal resulted in a statistically significant reduction in pneumothorax, patent ductus arteriosus, bronchopulmonary dysplasia (BPD), BPD or death at 28 days, and mortality" 09/01/1992 - "We found that, compared to one- and two-dose infants, those treated with three doses of Exosurf were more premature, smaller, required a longer ventilator course, and had more frequent complications, including patent ductus arteriosus (PDA), intraventricular hemorrhage, nosocomial pneumonia, and apnea" 11/01/1996 - "If the traditional measures preventing the possible volumic overloading of the pulmonary circulation in the presence of patent ductus arteriosus were not neglected, administration of exosurf to newborns with the respiratory distress syndrome did not lead to an increase in the frequency of hemodynamically significant FAD and pulmonary hemorrhages." Order ALL the reference details at left...

Therapies and Procedures

1.	Ligation 11/01/2003 - "CONCLUSIONS: Video-assisted thoracic surgery is a safe and effective technique for patent ductus arteriosus ligation in premature infants, including those with very low and extremely low birth weight." 06/01/1996 - "Open surgical ligation has proven to be a safe and effective method to bring about closure of the patent ductus arteriosus (PDA)" 06/01/1984 - "Results indicate that surgical ligation is a safe and effective procedure for treating patent ductus arteriosus with large left-to-right shunting in small premature infants." 12/01/1996 - "Cost and efficacy of surgical ligation versus transcatheter coil occlusion of patent ductus arteriosus." 04/01/1995 - "These data support the premise that children older than 3 months undergoing elective ligation of a patent ductus arteriosus have been treated with improved efficiency and less charge without an increase in postdischarge morbidity" Order ALL the reference details at left...
2.	Artificial Respiration (Mechanical Ventilation) 07/01/2002 - "Both patent ductus arteriosus and mechanical ventilation did not significantly influence the changes in LVO of VLBW infants at least before 36 hours of age" 11/01/1995 - "Early echocardiographic prediction of symptomatic patent ductus arteriosus in preterm infants undergoing mechanical ventilation." 09/01/1993 - "In conclusion, low renal function in these infants is further compromised by a patent ductus arteriosus and/or the use of mechanical ventilation." 09/01/1993 - "We attempted to elucidate if conditions requiring mechanical ventilation, including patent ductus arteriosus, might further compromise renal function due to decreased renal perfusion" 07/01/1987 - "To investigate whether the development of symptomatic patent ductus arteriosus could be predicted, 26 preterm infants dependent on mechanical ventilation were examined daily with Doppler and M-mode echocardiography until 3 days after birth" Order ALL the reference details at left...
3.	Thoracotomy 03/01/2004 - "OBJECTIVE: To overcome drawbacks of thoracotomy and percutaneous techniques, we have performed video-assisted thoracoscopic surgery (VATS) since 1991 to treat patent ductus arteriosus (PDA)" 07/27/2002 - "At one month of age she underwent closure of the patent ductus arteriosus and FloWatch implantation around the pulmonary artery through conventional left thoracotomy" 11/01/1998 - "Gas exchange and systemic perfusion were impaired compared with conventional interruption of the patent ductus arteriosus after thoracotomy." 03/01/1998 - "The puppy developed the lesion following a left thoracotomy to repair a patent ductus arteriosus" 02/01/1997 - "Thirty-six children (median chronological age 6 years 1 month) who had undergone surgical closure of a patent ductus arteriosus through a left posterolateral thoracotomy in the neonatal period (median gestational age 32 weeks) were investigated prospectively with respect to anatomical and functional changes of the chest" Order ALL the reference details at left...
4.	Cardiopulmonary Bypass (Heart-Lung Bypass) 05/01/2007 - "Closure of adult patent ductus arteriosus under cardiopulmonary bypass by using foley balloon catheter." 12/01/2003 - "The associated procedures were atrioseptostomy with cardiopulmonary bypass (2 patients), closure of patent ductus arteriosus (2 patients), and division of double aortic arch (1 patient)" 01/01/2003 - "Repair of recurrent patent ductus arteriosus in an adult with cardiopulmonary bypass." 12/01/2000 - "Operation for adult patent ductus arteriosus using cardiopulmonary bypass." 10/01/2000 - "This paper reports the unusual case of a 76-year-old woman who was discovered to have a hemodynamically significant patent ductus arteriosus following uneventful mitral valve replacement, utilizing cardiopulmonary bypass" Order ALL the reference details at left...
5.	Phototherapy (Light Therapy) 07/01/1986 - "The significant reduction of patent ductus arteriosus with shielding suggests that phototherapy may play a role in the occurrence of patent ductus arteriosus in premature infants" 11/01/2006 - "Patent ductus arteriosus in extremely preterm infants receiving phototherapy: does shielding the chest make a difference" 09/01/1993 - "We conclude that the use of phototherapy is associated with an increased incidence of patent ductus arteriosus in extremely low birth weight infants." 09/01/1993 - "Infants who received phototherapy (n = 128) had an increased incidence of patent ductus arteriosus compared with those who did not receive phototherapy (76% vs 53%)" 09/01/1993 - "Association of patent ductus arteriosus and phototherapy in infants weighing less than 1000 grams." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Patent Ductus Arteriosus

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 58 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>